Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine and 30 will serve as controls receiving placebo in a randomized double-blind fashion. Patients will be monitored through one year. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2* by MRI initially, at 6 and 12 months.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01395199
Study type Interventional
Source University of Campinas, Brazil
Contact
Status Completed
Phase Phase 3
Start date August 2012
Completion date February 2015

See also
  Status Clinical Trial Phase
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT02995707 - The Effective and Safety of Thalidomide in NTDT Phase 2
Active, not recruiting NCT01935661 - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Recruiting NCT05508932 - Atrial Fibrillation in Beta-Thalassemia
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Completed NCT01443312 - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Completed NCT00235391 - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Phase 3
Not yet recruiting NCT06058260 - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed NCT05529550 - Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Completed NCT04582110 - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting NCT06213402 - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)